Episode 391: 402. Functional disability after clinically significant extracranial bleeding: a secondary analysis of ASPREE

Episode 391: 402. Functional disability after clinically significant extracranial bleeding: a secondary analysis of ASPREE

https://www.jthjournal.org/article/S1538-7836(25)00109-6/fulltext
Antithrombotic agents, like aspirin and anticoagulants, are essential for treating many cardiovascular conditions. However, a common side effect is bleeding, with extracranial bleeding—bleeding outside the brain and spinal cord—being quite prevalent. This study, a secondary analysis of the Aspirin in Reducing Events in the Elderly, or ASPREE trial, aimed to explore how clinically significant extracranial bleeding affects the development of functional disability in otherwise healthy older adults.

What did the researchers find?

Summary of Findings:

  • Incidence of Bleeding: Out of nearly 19,000 participants, about 2.9%, or 547 individuals, experienced clinically significant extracranial bleeding.
  • Functional Independence Impact: Those who experienced such bleeding had a more than two-fold increase in the risk of developing dependence on activities of daily living, or ADLs. Specifically, the hazard ratio for ADL dependence was 2.46, indicating a significant association.
  • Types of Bleeding: Both gastrointestinal (GI) bleeding and other non-GI extracranial bleeding showed similar risks, with hazard ratios of 2.29 and 2.68 respectively. Importantly, these associations held true whether participants were on aspirin or a placebo.

Strengths of the Study:

  1. Large Sample Size: With nearly 19,000 participants, the study provides robust data.
  2. Rigorous Data Collection: Bleeding events were meticulously documented and adjudicated by medical professionals.
  3. Comprehensive Analysis: The detailed follow-up and frequent assessments allowed for thorough monitoring of participants' health outcomes over several years.

Weaknesses of the Study:

  1. Granular Data Absence: Specific details about hospitalization, such as length of stay or the number of transfusions, were not available.
  2. Data Collection Frequency: Bleeding events were assessed continuously, whereas ADL dependence was assessed biannually. This discrepancy could lead to challenges in pinpointing the exact onset of functional dependence relative to bleeding events.

Jaksot(387)

Episode 264: 263. Rates of Atrial Fibrillation 12 months After Onset of Hospitalized Transient AF

Episode 264: 263. Rates of Atrial Fibrillation 12 months After Onset of Hospitalized Transient AF

patients who have new-onset transient AF detected during a hospitalization for noncardiac surgery or medical illness and are discharged in sinus rhythm, approximately 1 in 3 have AF detected in the ye...

4 Huhti 20247min

Episode 263: 262. Does Omalizumab Help For Peanut Allergy?

Episode 263: 262. Does Omalizumab Help For Peanut Allergy?

Bottom line Omalizumab does seem to improve allergic reactions to peanuts but comes at a steep price tag. Likely only allergist will prescribe this drug but it is worth know about If you know or take ...

3 Huhti 20248min

Episode 262: 261. Are Combined Oral Contraceptives Effective for Treating Acne?

Episode 262: 261. Are Combined Oral Contraceptives Effective for Treating Acne?

At ~24 weeks, ~80-90% of females report improvement in their acne with COCs, compared to 50-80% placebo, and 30-50% will have clear-almost clear skin versus 10-40% on placebo. Efficacy appears similar...

2 Huhti 20249min

Episode 260: QM on Spring Break

Episode 260: QM on Spring Break

QM on Spring Break-- but do you like the new format? Andrewbuelt@gmail.com

20 Maalis 202452s

Episode 261: 260. SGLT2 Summary Recap

Episode 261: 260. SGLT2 Summary Recap

Diabetic patient- Empagliflozin prevents death from cardiovascular causes: NNT 46 per 3.1 yrs ($600 a month, 1 million dollars per life saved)-HFpEF- SGLT2 inhibitors do not prevent death and cost rou...

19 Maalis 20246min

Episode 259: 259. EMPULSE Trial- Empagliflozin and Win Ratios

Episode 259: 259. EMPULSE Trial- Empagliflozin and Win Ratios

These findings indicate that initiation of empagliflozin in patients hospitalized for acute heart failure is well tolerated and results in significant clinical benefit in the 90 days after starting tr...

18 Maalis 20249min

Episode 258: 258. SOLOIST-WHF -- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Episode 258: 258. SOLOIST-WHF -- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Primary Outcome: Composite of deaths from cardiovascular causes or hospitalizations and urgent visits for heart failureDeath was not improved!NNT of 5 for hospitalizations and urgent visits -- However...

15 Maalis 20249min

Episode 257: 256. EMPEROR-Reduced- Cardiovascular Outcomes with Empagliflozin in Heart Failure

Episode 257: 256. EMPEROR-Reduced- Cardiovascular Outcomes with Empagliflozin in Heart Failure

NNT of 20 to prevent 1 hospitalization at 16 months of follow upThey composite outcome was driven by decrease hospitalizations NOT deathhttps://www.nejm.org/doi/full/10.1056/NEJMoa2022190

14 Maalis 20249min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
voi-hyvin-meditaatiot-2
vakeva-elama-viisaampi-mieli-vahvempi-keho
tiedenaiset-podcast
psykopodiaa-podcast
rss-pitaisko-erota
puhu-muru
terapiassa
rss-uplevel-by-sonja-hannus
junnut-pelissa
rss-narsisti
rss-kuumilla-aalloilla
katilon-kahvitunti
selviytyjat-tarinoita-elamasta
rss-rakas-mielenterveyteni
rss-duodecim-lehti
meditaatiot-suomeksi
rss-ehjaksi
rss-vapaudu-voimaasi
rss-ayurglow-harmoninen-elama